---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-019084"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:46:43.203987+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Prelude Q1 net loss $29.5M ($0.63/sh); cash $266.2M funds into 2H2024; on track for data readouts in 2H2022

## Summary
- Net loss $29.5M ($0.63/sh) vs $21.3M ($0.47) YoY; R&D expense $22.8M ($16.5M) on increased clinical activity.
- Cash & equivalents $266.2M as of March 31, 2022, expected to fund operations into second half 2024.
- PRMT5 program (PRT811) expansion cohort data analysis ongoing; next steps decision in 2H2022.
- MCL1 inhibitor PRT1419 IV formulation prioritized; combination cohorts expected by mid-2022.
- Jane Huang appointed President and CMO effective April 4, 2022; previously CMO Hematology at BeiGene.

## SEC filing metadata
- accession: 0001564590-22-019084
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000156459022019084/0001564590-22-019084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000156459022019084/prld-8k_20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-019084
- JSON: https://secwatch.observer/filing/0001564590-22-019084.json
- Plain text: https://secwatch.observer/filing/0001564590-22-019084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.